Accendra Health, Inc.
NYSE:ACHMedical - Distribution
+$0.12 today
- Market cap
- $54.22M
- Beta
- 1.63
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$14.11
Volume 1.41M
Average 0.83M
ACH Interest Expense
Cost of servicing the company's debt during the period.
Accendra Health, Inc.NYSE: ACH
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense declines year over year
Q1 FY2026 interest expense of $32.87M fell 3.2% year over year, ahead of the -3.8% change in trailing-twelve-month interest expense. Sequentially, it rose 14.6% from the prior quarter. Over 3 fiscal years it compounded at +0.1% a year.
Context
- Interest expense amounted to 4.7% of revenue in FY2025, up 3.3 pp from a year earlier.
- Interest expense increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -3.2% holds above the trailing-twelve-month pace of -3.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 129.2M USD
- Year-over-year change
- -10.2%
- 4-year CAGR
- +28.0%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 129.2M | -10.2% |
| FY2024 | 2024-12-31 | 143.8M | -8.9% |
| FY2023 | 2023-12-31 | 157.92M | +22.5% |
| FY2022 | 2022-12-31 | 128.89M | +168.0% |
| FY2021 | 2021-12-31 | 48.09M | — |
Interest Expense vs competitors
How ACH compares with its peers on the latest reported figures
- Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -3.8% is the 5th highest of 10, against a peer median of -44.7%.
- Interest expense amounts to 5.0% of revenue for ACH, versus a peer median of 4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $136.75M USD | -3.8% | +0.1% | 5.0% | |
| LTM Mar 2026 | CA$40.92M CAD | -45.1% | -32.9% | 13.1% | |
| LTM Apr 2026 | CA$15.52M CAD | +10.1% | +10.4% | 2.3% | |
| LTM Mar 2026 | $7.02M USD | -67.3% | +57.6% | 6.0% | |
| LTM Mar 2026 | $5.92M USD | +21.0% | +228.1% | 10.0% | |
| LTM Mar 2026 | $2.61M USD | -44.7% | +4.8% | 3.3% | |
| LTM Mar 2026 | $2.35M USD | +125.1% | — | — | |
| LTM Mar 2026 | $1.23M USD | +270.1% | — | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $481K USD | -65.8% | +42.5% | 4.7% |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | -$1.14M USD | -151.6% | — | 3.0% | |
| Peer median (excluding ACH) | — | -44.7% | +26.4% | 4.0% | |
Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.79B | 9.96B | 10.33B | 10.7B | 2.76B |
| Cost of Revenue | 8.27B | 8.13B | 8.21B | 8.48B | 1.56B |
| Gross Profit | 1.51B | 1.83B | 2.13B | 2.22B | 1.2B |
| Gross Margin | 15.5% | 18.3% | 20.6% | 20.7% | 43.5% |
| Research & Development | 12.1M | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 1.08B | 1.55B | 1.81B | 1.91B | 1.05B |
| Operating Expenses | 1.14B | 1.68B | 2.02B | 2.43B | 1.05B |
| Depreciation & Amortization | 90.62M | 228.67M | 287.38M | 264.78M | 214.52M |
| EBITDA | 415.47M | 368.45M | 390.57M | 51.22M | 364.68M |
| EBITDA Margin | 4.2% | 3.7% | 3.8% | 0.5% | 13.2% |
| Operating Income | 368.47M | 142.91M | 104.51M | (207.77M) | 150.16M |
| Operating Margin | 3.8% | 1.4% | 1.0% | -1.9% | 5.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 48.09M | 128.89M | 157.92M | 143.8M | 129.2M |
| Other Income / Expenses | (91.72M) | (132.02M) | (159.23M) | (149.59M) | (252.11M) |
| Income Before Tax | 276.75M | 10.89M | (54.73M) | (357.36M) | (101.95M) |
| Pre-Tax Margin | 2.8% | 0.1% | -0.5% | -3.3% | -3.7% |
| Income Tax Expense | 55.17M | (11.5M) | (13.43M) | 5.33M | 729K |
| Net Income | 221.59M | 22.39M | (41.3M) | (362.69M) | (1.1B) |
| Net Margin | 2.3% | 0.2% | -0.4% | -3.4% | -39.8% |
| EPS (Basic) | 3.05 | 0.30 | (0.54) | (4.73) | (14.31) |
| EPS (Diluted) | 2.94 | 0.29 | (0.54) | (4.73) | (14.31) |
| Weighted Avg Shares | 72.74M | 74.5M | 75.79M | 76.74M | 76.9M |
| Weighted Avg Shares (Diluted) | 75.49M | 76.22M | 75.79M | 76.74M | 76.9M |
Accendra Health, Inc.
NYSE:ACH
Intrinsic Alpha fair value
Locked
Current Price
$0.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.